Synonyms: RO-0622
Compound class:
Synthetic organic
Comment: Azvudine is a nucleoside analogue that was first identified as an inhibitor of the HIV-1 RNA-dependent RNA polymerase (RdRp) [4]. It has more recently been reported to inhibit RdRp from the SARS-CoV-2 betacoronavirus [5]. The active triphosphate metabolite concentrates in the thymus and peripheral blood mononuclear cells, and oral treatment induces curative mechanisms in preclinical models.
|
|
References |
1. Bolinger AA, Li J, Xie X, Li H, Zhou J. (2024)
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov, 19 (9): 1023-1041. [PMID:39078037] |
2. da Silva RM, Gebe Abreu Cabral P, de Souza SB, Arruda RF, Cabral SPF, de Assis ALEM, Martins YPM, Tavares CAA, Viana Junior AB, Chang J et al.. (2023)
Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med (Lausanne), 10: 1143485. [PMID:37007788] |
3. de Souza SB, Cabral PGA, da Silva RM, Arruda RF, Cabral SPF, de Assis ALEM, Viana Junior AB, Degrave WMS, Moreira ADS, Silva CG et al.. (2023)
Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients. Front Med (Lausanne), 10: 1215916. [PMID:37928473] |
4. Sun L, Peng Y, Yu W, Zhang Y, Liang L, Song C, Hou J, Qiao Y, Wang Q, Chen J et al.. (2020)
Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. J Med Chem, 63 (15): 8554-8566. [PMID:32678592] |
5. Zhang JL, Li YH, Wang LL, Liu HQ, Lu SY, Liu Y, Li K, Liu B, Li SY, Shao FM et al.. (2021)
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther, 6 (1): 414. [PMID:34873151] |